Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT SHEPPARD

Allopathic & Osteopathic Physicians Internal Medicine Clinical Cardiac Electrophysiology

NPI
1578525937
CMS profile
25527
Location
ST PETERSBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,767.99

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,616.49 120
Travel and Lodging $4,151.50 18

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT SHEPPARD

NPI 1578525937 · CMS profile ID 25527

Allopathic & Osteopathic Physicians / Internal Medicine / Clinical Cardiac Electrophysiology

ST PETERSBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578525937?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT SHEPPARD, NPI 1578525937, CMS profile ID 25527. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578525937?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERT SHEPPARD, NPI 1578525937, CMS profile ID 25527. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578525937?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERT SHEPPARD, NPI 1578525937, CMS profile ID 25527, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578525937?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $9,767.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–138 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $13.2503/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001127 CMS
Abbott Laboratories $21.5203/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018075895 CMS
Abbott Laboratories $148.0503/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017941459 CMS
E.R. Squibb & Sons, L.L.C. $10.1603/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016180013 CMS
PFIZER INC. $14.4603/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049686403 CMS
ATRICURE, INC. $20.0203/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012058723 CMS
ATRICURE, INC. $24.1903/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012074477 CMS
SANOFI-AVENTIS U.S. LLC $16.7903/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049732453 CMS
Medtronic, Inc. $70.4603/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001269 CMS
Medtronic, Inc. $42.8803/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001277 CMS
Medtronic, Inc. $69.9903/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001285 CMS
Medtronic, Inc. $100.2603/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001111 CMS
Medtronic, Inc. $61.8203/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001235 CMS
Medtronic, Inc. $116.8803/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001243 CMS
Medtronic, Inc. $26.2403/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001251 CMS
Medtronic, Inc. $36.0403/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001261 CMS
Medtronic, Inc. $259.0003/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001315 CMS
Medtronic, Inc. $30.7103/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001323 CMS
Boston Scientific Corporation $17.4503/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022456469 CMS
Medtronic, Inc. $144.2903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001227 CMS
Medtronic, Inc. $259.0003/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001293 CMS
Medtronic, Inc. $60.5103/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001303 CMS
ATRICURE, INC. $26.5203/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012079439 CMS
Biosense Webster, Inc. $6.8802/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990909575 CMS
Biosense Webster, Inc. $19.3802/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990909569 CMS
Kerecis Limited $16.2002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056302025 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $16.6801/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984087571 CMS
Medtronic, Inc. $66.9401/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001155 CMS
PFIZER INC. $17.5701/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049137543 CMS
Actelion Pharmaceuticals US, Inc. $14.3001/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988581591 CMS
E.R. Squibb & Sons, L.L.C. $9.3401/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016179927 CMS
Biosense Webster, Inc. $10.7001/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990909563 CMS
Medtronic, Inc. $12.7201/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001055 CMS
ShockWave Medical, Inc $168.1901/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058517715 CMS
Medtronic, Inc. $10.8501/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026001047 CMS
Abbott Laboratories $11.4801/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017893765 CMS
Abbott Laboratories $14.5401/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019146293 CMS
E.R. Squibb & Sons, L.L.C. $3.0601/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016179921 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,294.15 118
PY2020 $4,700.88 104
PY2021 $7,784.18 144
PY2022 $9,856.84 131
PY2023 $9,767.99 138
PY2024 $2,863.59 86
PY2025 $8,000.60 92

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $148,076.00 18
PY2024 Principal investigator $79,234.00 14
PY2023 Principal investigator $5,010.00 2
PY2020 Principal investigator $2,045.00 3
PY2019 Principal investigator $364.07 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,146.00 12/12/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270715
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/03/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175271239
Principal investigator 1 Janssen Research & Development, LLC $3,333.00 11/19/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270701
Principal investigator 1 Janssen Research & Development, LLC $5,536.00 11/07/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270654
Principal investigator 1 Janssen Research & Development, LLC $2,347.00 11/03/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175271000
Principal investigator 1 Janssen Research & Development, LLC $4,929.00 09/19/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270976
Principal investigator 1 Janssen Research & Development, LLC $159.00 09/12/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270586
Principal investigator 1 Janssen Research & Development, LLC $9,663.00 08/25/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175271231
Principal investigator 1 Janssen Research & Development, LLC $2,354.00 08/13/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270949
Principal investigator 1 Janssen Research & Development, LLC $250.00 08/11/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175271184
Principal investigator 1 Janssen Research & Development, LLC $4,941.00 07/23/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270815
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 07/09/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270725
Principal investigator 1 Janssen Research & Development, LLC $16,610.00 07/02/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270966
Principal investigator 1 Janssen Research & Development, LLC $1,154.00 06/23/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175271106
Principal investigator 1 Janssen Research & Development, LLC $79,385.00 06/20/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270688
Principal investigator 1 Janssen Research & Development, LLC $6,969.00 04/23/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270917
Principal investigator 1 Janssen Research & Development, LLC $250.00 03/19/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175271295
Principal investigator 1 Janssen Research & Development, LLC $2,050.00 01/22/2025 Non-covered Recipient Entity
Hca Rsrch Inst Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175270546